Adimab Expands Executive Team with Addition of Philip T. Chase as General Counsel Guy Van Meter Promoted to Vice President of Business Development

January 05, 2012 Lebanon, NH PDF

Adimab, LLC, a leader in the discovery of fully human antibodies, today announced that Philip T. Chase has joined the company as General Counsel. Mr. Chase comes to Adimab with extensive legal and dealmaking experience in the biotechnology industry. Most recently, Mr. Chase served as the General Counsel at Alnylam Pharmaceuticals where he oversaw all legal functions during a time when Alnylam executed and managed numerous significant partnerships, including large technology collaborations with Roche and Takeda.

“We are very pleased to add an individual as experienced as Phil to our executive management team,” said Errik Anderson, Adimab’s Co-Founder and Chief Operating Officer. “Phil’s involvement with strategic technology partnerships and alliance management at Alnylam and Transkaryotic Therapies will add depth and capabilities as we execute on Adimab’s strategy.”

In addition, Adimab today announced the promotion of Guy Van Meter to Vice President, Head of Business Development, with responsibility for all business development activities at Adimab.

“For the past 3 years, Guy has been driving our business development efforts and has been instrumental in establishing partnerships with Merck, Roche, Pfizer, Novartis, Lilly, Genentech, Biogen Idec, Novo Nordisk, and others,” explained Tillman Gerngross, Adimab’s Co-Founder and Chief Executive Officer. “This promotion both recognizes Guy’s past contributions to Adimab, as well as expands his responsibility to structuring longer term strategic partnerships that may involve broad access to Adimab’s antibody discovery platform.”

About Philip T. Chase

Prior to Adimab, Mr. Chase served as the General Counsel at Alnylam Pharmaceuticals where he oversaw all legal functions and had a prominent role in Alnylam’s business development activities. Before that, Mr. Chase served as Vice President and General Counsel of EPIX Pharmaceuticals, Inc. and played an integral role in the merger of EPIX and Predix Pharmaceuticals Holdings, Inc. Mr.

Chase also served as Chief Corporate Counsel at Transkaryotic Therapies, Inc. and played an integral role in the sale of that company to Shire plc. Prior to moving into the biotechnology industry, Mr. Chase worked at the law firms of Skadden, Arps, Slate, Meagher & Flom LLP, and Shearman & Sterling LLP. He received his J.D. degree from Columbia University School of Law and his BA from Colby College.

About Guy Van Meter

Mr. Van Meter has served as Senior Director of Business Development for Adimab for the past 3 years. Prior to Adimab, Mr. Van Meter was in a business development and strategic alliance role at Pfizer within the Pfizer Biotherapeutics and Bioinnovation Center. Mr. Van Meter has also served in business development at Dyax Corp. where he managed the technology licensing business. Prior work experience includes a regulatory product development role at Alkermes, Inc., and research at Harvard-Brigham and Women’s and Yale University School of Medicine. Mr. Van Meter holds an MBA from the F.W. Olin Graduate School of Business at Babson College.

About Adimab

Adimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.


Guy Van Meter
VP, Head of Business Development
(603) 727-7107 x175

Chris Erdman
MacDougall Biomedical Communications
(781) 235-3060